Cargando…
Dendritic cell-based vaccination in metastatic melanoma patients: Phase II clinical trial
Metastatic and chemoresistant melanoma can be a good target of immunotherapy because it is an intractable cancer with a very poor prognosis. Previously, we tested a dendritic cell (DC)-based phase I vaccine, and confirmed that it was safe. In the present study, we performed a phase II trial of a DC...
Autores principales: | OSHITA, CHIE, TAKIKAWA, MASAKO, KUME, AKIKO, MIYATA, HARUO, ASHIZAWA, TADASHI, IIZUKA, AKIRA, KIYOHARA, YOSHIO, YOSHIKAWA, SHUSUKE, TANOSAKI, RYUJI, YAMAZAKI, NAOYA, YAMAMOTO, AKIFUMI, TAKESAKO, KAZUTOH, YAMAGUCHI, KEN, AKIYAMA, YASUTO |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
D.A. Spandidos
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3583475/ https://www.ncbi.nlm.nih.gov/pubmed/22895835 http://dx.doi.org/10.3892/or.2012.1956 |
Ejemplares similares
-
Clinical response in Japanese metastatic melanoma patients treated with peptide cocktail-pulsed dendritic cells
por: Akiyama, Yasuto, et al.
Publicado: (2005) -
Immunologically augmented skin flap as a novel dendritic cell vaccine against head and neck cancer in a rat model
por: Inoue, Keita, et al.
Publicado: (2015) -
α-type-1 polarized dendritic cell-based vaccination in recurrent high-grade glioma: a phase I clinical trial
por: Akiyama, Yasuto, et al.
Publicado: (2012) -
High-dose proton beam therapy for sinonasal mucosal malignant melanoma
por: Fuji, Hiroshi, et al.
Publicado: (2014) -
Phase 1/2 study assessing the safety and efficacy of dabrafenib and trametinib combination therapy in Japanese patients with BRAF V600 mutation‐positive advanced cutaneous melanoma
por: Yamazaki, Naoya, et al.
Publicado: (2018)